S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Abbott Laboratories Outlook is Healthy: Buy the Dip
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Abbott Laboratories Outlook is Healthy: Buy the Dip
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Abbott Laboratories Outlook is Healthy: Buy the Dip
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Abbott Laboratories Outlook is Healthy: Buy the Dip
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$23.45
+1.5%
$31.21
$22.42
$59.61
$1.12B1.38753,621 shs1.06 million shs
Glaukos Co. stock logo
GKOS
Glaukos
$96.96
+0.0%
$91.90
$45.38
$102.33
$4.80B1.08521,054 shs288,650 shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
$51.79
-0.4%
$49.04
$24.83
$54.50
$2.65B1.01434,641 shs725,914 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+1.52%-9.46%-26.58%-28.94%-43.72%
Glaukos Co. stock logo
GKOS
Glaukos
+0.02%-2.76%+13.47%+6.81%+100.62%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-7.10%
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-0.38%-0.84%+6.34%+14.81%+39.90%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
1.6503 of 5 stars
3.51.00.00.01.92.50.6
Glaukos Co. stock logo
GKOS
Glaukos
3.4793 of 5 stars
2.42.00.04.43.22.50.6
NuVasive, Inc. stock logo
NUVA
NuVasive
1.8759 of 5 stars
3.30.00.00.00.00.03.1
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
0.4502 of 5 stars
1.51.00.00.01.93.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$55.57136.98% Upside
Glaukos Co. stock logo
GKOS
Glaukos
2.78
Moderate Buy$99.802.93% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
3.00
Buy$45.60-11.95% Downside

Current Analyst Ratings

Latest GKOS, ATRC, NUVA, and PRCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
Glaukos Co. stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $100.00
4/10/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00
4/8/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
4/3/2024
Glaukos Co. stock logo
GKOS
Glaukos
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
3/25/2024
Glaukos Co. stock logo
GKOS
Glaukos
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$107.00 ➝ $120.00
3/22/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
2/28/2024
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$55.00 ➝ $58.00
2/22/2024
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$83.00 ➝ $103.00
2/22/2024
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$105.00 ➝ $108.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $58.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $42.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$399.24M2.84N/AN/A$9.84 per share2.38
Glaukos Co. stock logo
GKOS
Glaukos
$314.71M15.24N/AN/A$9.46 per share10.25
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
$136.19M19.38N/AN/A$5.56 per share9.31

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.66N/AN/AN/A-7.62%-7.55%-5.83%5/1/2024 (Confirmed)
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.78N/AN/AN/A-42.79%-22.67%-11.50%5/1/2024 (Confirmed)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-$105.90M-$2.24N/AN/AN/A-77.75%-46.59%-30.63%5/1/2024 (Confirmed)

Latest GKOS, ATRC, NUVA, and PRCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.20N/A+$0.20N/AN/AN/A  
5/1/2024N/A
Glaukos Co. stock logo
GKOS
Glaukos
-$0.59N/A+$0.59N/AN/AN/A  
5/1/2024N/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-$0.55N/A+$0.55N/AN/AN/A  
2/27/2024Q4 2023
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-$0.44-$0.54-$0.10-$0.54$41.79 million$43.58 million      
2/21/2024Q4 2023
Glaukos Co. stock logo
GKOS
Glaukos
-$0.56-$0.63-$0.07-$0.51$81.00 million$82.40 million    
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.15
3.57
2.66
Glaukos Co. stock logo
GKOS
Glaukos
0.77
5.34
4.78
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
0.18
7.63
6.77

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
89.46%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Glaukos Co. stock logo
GKOS
Glaukos
7.80%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
19.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20048.38 million46.83 millionOptionable
Glaukos Co. stock logo
GKOS
Glaukos
90749.47 million45.61 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
62650.96 million40.98 millionOptionable

GKOS, ATRC, NUVA, and PRCT Headlines

SourceHeadline
PROCEPT BioRobotics Co. (NASDAQ:PRCT) Stake Lowered by Allspring Global Investments Holdings LLCPROCEPT BioRobotics Co. (NASDAQ:PRCT) Stake Lowered by Allspring Global Investments Holdings LLC
marketbeat.com - April 18 at 5:22 AM
Contrasting SeaStar Medical (NASDAQ:ICU) & PROCEPT BioRobotics (NASDAQ:PRCT)Contrasting SeaStar Medical (NASDAQ:ICU) & PROCEPT BioRobotics (NASDAQ:PRCT)
americanbankingnews.com - April 16 at 3:20 AM
PROCEPT BioRobotics (NASDAQ:PRCT) Trading Up 3.5%PROCEPT BioRobotics (NASDAQ:PRCT) Trading Up 3.5%
marketbeat.com - April 15 at 5:31 PM
PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 12-Month High at $53.54PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 12-Month High at $53.54
americanbankingnews.com - April 13 at 5:04 AM
PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 12-Month High at $53.54PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 12-Month High at $53.54
marketbeat.com - April 11 at 10:45 AM
Experts Top 5 AI Stocks With Huge PotentialExperts Top 5 AI Stocks With Huge Potential
msn.com - April 8 at 7:34 PM
PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 4.4%PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 4.4%
marketbeat.com - April 5 at 2:18 PM
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, TexasPROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
globenewswire.com - April 4 at 4:04 PM
Ballentine Partners LLC Purchases Shares of 133,000 PROCEPT BioRobotics Co. (NASDAQ:PRCT)Ballentine Partners LLC Purchases Shares of 133,000 PROCEPT BioRobotics Co. (NASDAQ:PRCT)
marketbeat.com - April 3 at 5:38 PM
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
globenewswire.com - April 2 at 4:03 PM
PROCEPT BioRobotics Co. (NASDAQ:PRCT) Receives Consensus Rating of "Buy" from AnalystsPROCEPT BioRobotics Co. (NASDAQ:PRCT) Receives Consensus Rating of "Buy" from Analysts
marketbeat.com - April 2 at 4:22 AM
Brokers Issue Forecasts for PROCEPT BioRobotics Co.s Q2 2025 Earnings (NASDAQ:PRCT)Brokers Issue Forecasts for PROCEPT BioRobotics Co.'s Q2 2025 Earnings (NASDAQ:PRCT)
marketbeat.com - March 31 at 1:48 AM
Wellington Management Group LLP Takes $26.40 Million Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)Wellington Management Group LLP Takes $26.40 Million Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)
marketbeat.com - March 22 at 4:25 AM
Insider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Sells 441 Shares of StockInsider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Sells 441 Shares of Stock
insidertrades.com - March 21 at 10:33 AM
Insider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Sells 1,024 Shares of StockInsider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Sells 1,024 Shares of Stock
insidertrades.com - March 21 at 10:32 AM
American Century Companies Inc. Has $21.50 Million Stock Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)American Century Companies Inc. Has $21.50 Million Stock Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)
marketbeat.com - March 21 at 4:13 AM
PROCEPT BioRobotics Corp (PRCT) President and CEO Reza Zadno Sells Company SharesPROCEPT BioRobotics Corp (PRCT) President and CEO Reza Zadno Sells Company Shares
finance.yahoo.com - March 20 at 7:23 PM
PRCT Oct 2024 55.000 callPRCT Oct 2024 55.000 call
finance.yahoo.com - March 18 at 10:46 AM
Alaleh Nouri Sells 2,749 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) StockAlaleh Nouri Sells 2,749 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) Stock
insidertrades.com - March 17 at 8:17 AM
PRCT Apr 2024 50.000 putPRCT Apr 2024 50.000 put
ca.finance.yahoo.com - March 16 at 9:52 AM
EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics Corp (PRCT)EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics Corp (PRCT)
finance.yahoo.com - March 8 at 9:35 AM
Director Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)Director Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)
finance.yahoo.com - March 7 at 12:14 AM
Noteworthy Wednesday Option Activity: ZM, PRCT, MSTRNoteworthy Wednesday Option Activity: ZM, PRCT, MSTR
nasdaq.com - March 1 at 2:13 PM
PROCEPT BioRobotics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsPROCEPT BioRobotics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
finance.yahoo.com - March 1 at 9:12 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Glaukos logo

Glaukos

NYSE:GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.
PROCEPT BioRobotics logo

PROCEPT BioRobotics

NASDAQ:PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.